Financial Comparison: Stryker (NYSE:SYK) vs. DiaSorin (OTCMKTS:DSRLF)

Stryker (NYSE:SYK) and DiaSorin (OTCMKTS:DSRLF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility and Risk

Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, DiaSorin has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.

Institutional & Insider Ownership

77.1% of Stryker shares are owned by institutional investors. 4.6% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Stryker and DiaSorin”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$25.12 billion	4.76	$3.25 billion	$8.64	36.13
DiaSorin	$1.28 billion	3.59	$203.55 million	N/A	N/A

Stryker has higher revenue and earnings than DiaSorin.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Stryker and DiaSorin, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	0	6	16	0	2.73
DiaSorin	0	5	2	0	2.29

Stryker presently has a consensus target price of $395.33, suggesting a potential upside of 26.65%. Given Stryker’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Stryker is more favorable than DiaSorin.

Profitability

This table compares Stryker and DiaSorin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stryker	13.20%	23.42%	11.04%
DiaSorin	N/A	N/A	N/A

Summary

Stryker beats DiaSorin on 12 of the 12 factors compared between the two stocks.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

About DiaSorin

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.